Clinical Trials
17 trialsNCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT01195649 2019-06-04
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Bayer
Terminated
NCT01411423 2018-06-06
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Bayer
Completed
NCT01412671 2018-06-06
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Bayer
Completed
NCT01982097 2018-02-07
SANE
Bayer
Completed
NCT01728948 2017-11-09
Sorafenib in Elderly mRCC
Bayer
Completed
NCT01557127 2017-03-28
NEXST
Bayer
Completed
NCT01012011 2015-09-21
Regulatory Post Marketing Surveillance Study on Nexavar®
Bayer
Completed
NCT01507740 2015-04-29
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Terminated
NCT01353794 2015-01-30
POWER-NEXT
Bayer
Withdrawn
NCT01508364 2015-01-21
NEXTAR
Bayer
Completed
NCT01449825 2014-04-21
Hepatic Monitoring for Pazopanib
GlaxoSmithKline
Completed
NCT01381601 2013-05-13
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
GlaxoSmithKline
Completed
NCT01381614 2013-05-13
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
GlaxoSmithKline
Completed
NCT00771147 2012-06-15
PONDIAC
Bayer
Completed
NCT01230697 2010-10-29
SORHORM
University of Turin, Italy
Unknown
NCT00895674 2010-09-30
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Bayer
Completed